Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy.

Long-Term Follow-up of CAR T-Cell–Treated Lymphoma Progression-free survival at 5 years was 31% in patients with diffuse large B-cell lymphoma and 43% in patients with follicular lymphoma. A total ...